Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cullinan Therapeutics, Inc. (CGEM : NSDQ)

• Company Description    Cullinan Therapeutics Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. The company's product pipeline consists CLN-978. Cullinan Therapeutics Inc., formerly known as Cullinan Oncology Inc., is based in CAMBRIDGE, Mass. Number of Employees: 111

• Price / Volume Information    Yesterday's Closing Price: $7.84 Daily Weekly Monthly 20 Day Moving Average: 339,292 shares Shares Outstanding: 59.01 (millions) Market Capitalization: $462.67 (millions) Beta: -0.08 52 Week High: $21.01 52 Week Low: $6.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.40% -15.68% 12 Week -0.63% -16.42% Year To Date -35.63% -39.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE MAIN STREET SUITE 1350 - CAMBRIDGE,MA 02142 USA ph: 617-410-4650 fax: - cmesser@cullinanoncology.com http://www.cullinanoncology.com

• General Corporate Information    Officers Nadim Ahmed - Chief Executive Officer; President and Director Mary Kay Fenton - Chief Financial Officer Jacquelyn Sumer - Chief Legal Officer; Chief Compliance Officer and Anne-Marie Martin - Director David Meek - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 230031106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 59.01 Most Recent Split Date: (:1) Beta: -0.08 Market Capitalization: $462.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.80 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.84 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 13.95% vs. Previous Quarter: -1.37% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -29.47 12/31/24 - -29.11 ROA 06/30/25 - - 03/31/25 - -28.19 12/31/24 - -27.83 Current Ratio 06/30/25 - - 03/31/25 - 11.62 12/31/24 - 13.53 Quick Ratio 06/30/25 - - 03/31/25 - 11.62 12/31/24 - 13.53 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 9.35 12/31/24 - 10.14 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©